• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Mostafa, M., Morsy, E., Maklad, H., Elrahmany, S., Mohamed Haji, S. (2024). Serum calprotectin in patients with type 2 diabetes mellitus and its relation to microvascular complications.. ALEXMED ePosters, 6(2), 13-14. doi: 10.21608/alexpo.2024.287807.1833
Mabaheg Mostafa; Eman Youssef Morsy; Hala Maklad; Shimaa Mohamed Elrahmany; Said Ahmed Mohamed Haji. "Serum calprotectin in patients with type 2 diabetes mellitus and its relation to microvascular complications.". ALEXMED ePosters, 6, 2, 2024, 13-14. doi: 10.21608/alexpo.2024.287807.1833
Mostafa, M., Morsy, E., Maklad, H., Elrahmany, S., Mohamed Haji, S. (2024). 'Serum calprotectin in patients with type 2 diabetes mellitus and its relation to microvascular complications.', ALEXMED ePosters, 6(2), pp. 13-14. doi: 10.21608/alexpo.2024.287807.1833
Mostafa, M., Morsy, E., Maklad, H., Elrahmany, S., Mohamed Haji, S. Serum calprotectin in patients with type 2 diabetes mellitus and its relation to microvascular complications.. ALEXMED ePosters, 2024; 6(2): 13-14. doi: 10.21608/alexpo.2024.287807.1833

Serum calprotectin in patients with type 2 diabetes mellitus and its relation to microvascular complications.

Article 1, Volume 6, Issue 2, April 2024, Page 13-14  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2024.287807.1833
View on SCiNiTO View on SCiNiTO
Authors
Mabaheg Mostafa1; Eman Youssef Morsy2; Hala Maklad3; Shimaa Mohamed Elrahmany4; Said Ahmed Mohamed Haji email 5
1Department of diabetes, Faculty of Medicine, Alexandria university
2Department of Internal Medicine, Faculty of Medicine, University of Alexandria
3Department of physiology, Faculty of medicine, Alexandria Univerdity
4Department of diabetes, Faculty of Medicine, Alexandria University
5Department of internal Medicine, Faculty of Medicine, Alexandria university
Abstract
DM is a leading cause of mortality, morbidity and reduced life expectancy.It is characterized by chronic hyperglycemia and altered cellular homeostasis, which lead to diffuse vascular damage and multi-organ dysfunction. In long term, patients with DM risk developing both micro- and macrovascular complications. Insulin resistance is defined as decreased sensitivity and responsiveness to insulin-mediated glucose disposal and inhibition of hepatic glucose production and plays a significant pathophysiologic role in T2DM.
Calprotectin is a soluble protein in white blood cells and is actively secreted during the stress response of phagocytes and is associated with inflammation and is found to be increased in subjects with insulin resistance.

AIM OF THE WORK:
This study was conducted to:
1. Measure serum calprotectin in patients with T2DM.
2. Evaluate the relationship between serum calprotectin and insulinresistance in patients with T2DM.
3. Evaluate the relationship between serum calprotectin and microvascularcomplications (diabetic kidney disease, neuropathy and retinopathy) inpatients with T2DM.

SUBJECTS AND METHODS:
SUBJECTS
This case study was conducted on 100 patients with type 2 diabetes mellitus divided into two groups, Group (1): 50 patients with T2DM, further divided into 2 subgroups: Subgroup (1A): 25 patients with T2DM and microvascular complications. Subgroup (1B): 25 patients with T2DM without microvascular complications. Group (2): 50 normal subjects of matched age and sex as a control group.
Patients were recruited from the outpatient clinic of the Diabetes unit Alexandria Main University hospital.
Full informed consent was
Keywords
Serum calprotectin; microvascular complications; diabetes type 2
Supplementary Files
download 1833 20 (32).pdf
Statistics
Article View: 106
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.